Australia Health

Island Pharmaceuticals (ASX:ILA) launched a comprehensive GMP manufacturing campaign for antiviral candidate Galidesivir.

Pro Medicus (ASX:PME) has secured a major five-year, $16 million contract renewal with The Ohio State University Wexner Medical Centre.

Cynata Therapeutics (ASX:CYP) has received a positive opinion from the European Medicines Agency’s paediatric committee.

Firebrick Pharma (ASX:FRE) said its patent covering the composition of Nasodine nasal spray has been granted in New Zealand.

Cancer diagnostics company Pacific Edge (ASX:PEB) has finalised a NZ$36.1 million capital raising campaign.

Imagion Biosystems (ASX:IBX) achieved a regulatory milestone following formal Investigational New Drug clearance from the US FDA.

4DMedical (ASX:4DX) has launched CLEAR, a clinical evidence programme designed to fast-track its proprietary CT:VQ technology.

Memphasys (ASX:MEM) has secured its first commercial partnership in Southeast Asia.

ReNerve (ASX:RNV) entered an exclusive three-year deal with Swedish Trading to commercialise its NervAlign nerve repair products.

4DMedical (ASX:4DX) announced a binding agreement to acquire the Austrian-based medical technology company contextflow.

Pro Medicus (ASX:PME) has secured two major contract wins in the United States, totalling $44 million.

Paragon Care (ASX:PGC) issued an update regarding its financial exposure to the receivership of the Infinity Retail Pharmacy Group.